ClinicalTrials.Veeva

Menu

INTERACT4 Expansion - Validation Study

T

The George Institute

Status

Not yet enrolling

Conditions

Intracerebral Hemorrhage

Treatments

Diagnostic Test: LVOne

Study type

Observational

Funder types

Other

Identifiers

Details and patient eligibility

About

As an investigator-initiated and conducted, multi-centre, open-label, single-arm prospective observational trial, INTERACT4 Expansion aims to evaluate the diagnostic accuracy of GFAP measured using a point-of-care device, for identifying ICH in participants presenting with acute stroke-like symptoms in the pre-hospital setting compared with imaging-confirmed ICH.

Enrollment

465 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Adults (age ≥18 years);
  2. Acute syndrome that is due to presumed acute stroke, defined as FAST (Face, Arm, Speech, Time) scores of ≥2 with an arm motor deficit;
  3. Time ≤3 hours from last seen well;
  4. Systolic BP (SBP) ≥150mmHg.

Exclusion criteria

  1. Participants in coma (no response to tactile/verbal stimulation); or/and do not respond to "P" or "U" on the alert/verbal/painful/unresponsive (APVU) responsiveness scale;
  2. Severe known co-morbid disease (e.g. cancer, chronic airflow disease, severe dementia, severe heart failure, pre-existing disability [needing help]);
  3. Known history of epilepsy or seizure at onset;
  4. Recent head injury (where there is potential for another type of intracranial haemorrhage or head trauma);
  5. Hypoglycaemia (glucose<4.0 mmol/L) as measured in the ambulance.

Trial contacts and locations

4

Loading...

Central trial contact

Craig Anderson, MD; Cheryl Carcel, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems